The focus of this theme is the organ specific consequences of metabolic stress from diet, life style and the environment. Projects truly go from bench-to-bedside, bedside-to-bench and clinic to community. The research tools we utilize ranging from cell and animal models to clinical phenotyping in humans, with invasive and imaging techniques and on to large cohorts and routine health data. Our aim is to extend the traditional translational model by both actively supporting research that translates fundamental discoveries in basic science as well as attempting to elucidate the biological mechanisms underlying the role of candidate susceptibility genes (Translational Genomics). Our translational research agenda is supported by the Tayside Medical Science Centre, a state-of-the-art Clinical Research Centre, the Tayside Tissue Bank and core research facilities for biomarker development, cardiometabolic phenotyping and imaging. The Drug Discovery Unit in CLS offers facilities for stage 1 drug discovery following target identification, and our PIs have a number of projects that exploit this resource.
Mike Ashford, Calum Sutherland, Rory McCrimmon, Li Kang, John Dillon (Gut Research Group), Will Fuller, Graeme Rena, Aleksandar Jovanovic, Faisal Kahn, Graeme Houston act as a bridge between the strong biomedical research carried out in CMDN and CLS. Our aim is to find targets, pathways and solutions for the major disease clusters associated with the lifestyle and dietary choices of modern living. This includes heart disease, vascular disease, diabetes, dementia and neuro-degeneration as well as liver disease.